Malignant Penile Neoplasm — Trials

Malignant Penile Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

94 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 43
Recruiting: 22
Ph III recruiting: 0
Growth YoY: —
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: —
Trials / 1,000 deaths: 120.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04985357	Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs	withdrawn	—	0	Travera IncINDUSTRY	0	Nov 25, 2024	clinicaltrials
NCT02014831	Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE)	withdrawn	Phase 2	0	Centre Leon BerardOTHER	1	Feb 25, 2016	clinicaltrials